KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Medtronic (MDT) Research & Development (2016 - 2026)

Medtronic's Research & Development history spans 13 years, with the latest figure at $722.0 million for Q1 2026.

  • For Q1 2026, Research & Development rose 6.96% year-over-year to $722.0 million; the TTM value through Jan 2026 reached $2.9 billion, up 5.99%, while the annual FY2025 figure was $2.7 billion, 0.11% changed from the prior year.
  • Research & Development for Q1 2026 was $722.0 million at Medtronic, down from $754.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $754.0 million in Q4 2025 and bottomed at $641.0 million in Q2 2023.
  • The 5-year median for Research & Development is $684.0 million (2025), against an average of $687.4 million.
  • The largest YoY upside for Research & Development was 11.15% in 2022 against a maximum downside of 7.73% in 2022.
  • A 5-year view of Research & Development shows it stood at $676.0 million in 2022, then rose by 3.11% to $697.0 million in 2023, then changed by 0.0% to $697.0 million in 2024, then rose by 8.18% to $754.0 million in 2025, then fell by 4.24% to $722.0 million in 2026.
  • Per Business Quant, the three most recent readings for MDT's Research & Development are $722.0 million (Q1 2026), $754.0 million (Q4 2025), and $726.0 million (Q3 2025).